1. Show article details.

    Apple gains ahead of earnings; Deutsche Bank hit by legal costs

    MarketWatch – 11:25 AM ET 04/27/2015

    These are the stocks making notable moves in Monday trade:. Apple Inc. (AAPL) is projected to report late Monday fiscal second-quarter earnings of $2.15 a share, according to a consensus survey by FactSet. Analysts will watch how well iPhone 6 and 6 Plus models sold in China, an important market for growth.

  2. Show article details.

    Teva says it's 'fully committed' to Mylan merger

    MarketWatch – 10:57 AM ET 04/27/2015

    Teva Pharmaceutical Industries Ltd. (TEVA) said Monday it was "fully committed" to its $43 billion bid for fellow generic drug maker Mylan NV (MYL), despite Mylan's rejection, issued earlier in the day. Teva maintained the bid, involving an equal mix of cash and stock, is "extremely attractive" for Mylan shareholders, noting that it represents a 48.3% premium to the company's shares on March 10, just before speculation about a possible combination surfaced. Earlier on Monday, Mylan issued a harsh...

  3. Show article details.

    Mylan Rejects Teva's Unsolicited $40 Billion Bid

    DJ Business News – 10:45 AM ET 04/27/2015

    Mylan N.V. (MYL) said its board unanimously rejected the unsolicited bid from Teva Pharmaceutical Industries Ltd. (TEVA), the latest move in a three-way tussle in a generic-drug industry facing challenges from slowing growth. A Teva spokesman wasn't immediately available to comment. Mylan also said Monday that it remains committed to its $33 billion offer for Perrigo Co. (PRGO), which some have seen as an effort to prevent a potential purchase by Teva.

  4. Show article details.

    Teva Reiterates Commitment to Cash-and-Stock Acquisition of Mylan for $82.00 Per Share

    Business Wire – 10:37 AM ET 04/27/2015

    Teva Pharmaceutical Industries Ltd. (TEVA) today reiterated its commitment to its proposed combination with Mylan N.V. (MYL) . As previously announced on April 21, 2015, Teva has proposed to acquire Mylan for $82.00 per share, with the consideration to be comprised of approximately 50 percent cash and 50 percent stock.

  5. Show article details.

    Mylan Rejects Teva's Unsolicited $40 Billion Bid

    DJ Business News – 10:35 AM ET 04/27/2015

    Mylan N.V. (MYL) said its board unanimously rejected the unsolicited bid from Teva Pharmaceutical Industries Ltd. (TEVA), the latest move in a three-way tussle in a generic-drug industry facing challenges from slowing growth. A Teva spokesman wasn't immediately available to comment. Mylan also said Monday that it remains committed to its $33 billion offer for Perrigo Co. (PRGO), which some have seen as an effort to prevent a potential purchase by Teva.

  6. Show article details.

    Mylan's stock falls after company rejects Teva's hostile buyout bid

    MarketWatch – 9:42 AM ET 04/27/2015

    Mylan N.V.' s stock slumped 3% in morning trade Monday, after the drug maker said its board of directors unanimously rejected Teva Pharmaceutical's unsolicited buyout bid. Mylan said it not only believes the bid Teva made early last week, which would value Mylan at about $40 billion, did not meet any of the key criteria that would cause the company to depart from its current course. "After thorough consideration, Mylan's Board unanimously determined that Teva's proposal grossly...

  7. Show article details.

    Mylan Board Unanimously Rejects Unsolicited Expression of Interest from Teva

    PR Newswire – 9:19 AM ET 04/27/2015

    POTTERS BAR, England, April 27, 2015Mylan N.V. (MYL) today announced that its Board of Directors has unanimously rejected the unsolicited expression of interest from Teva Pharmaceutical Industries, Ltd. (TEVA) to acquire Mylan, which was announced by Teva on April 21, 2015.

  8. Show article details.

    Mylan Raises Bid for Generic Drug Maker Perrigo -- 5th Update

    DJ Business News – 12:48 PM ET 04/24/2015

    Mylan NV (MYL) raised its offer to buy generic drug maker Perrigo Co. (PRGO) to about $33 billion and was promptly rebuffed, the latest moves in a three-way takeover tussle in the pharmaceutical industry. Mylan's bid consists of $60 in cash and 2.2 Mylan shares for each share of Perrigo (PRGO). Based on Thursday's close, the offer values Perrigo (PRGO) at about $222 a share.

  9. Show article details.

    Offer Rejection

    Business Wire – 12:33 PM ET 04/24/2015

    PERRIGO REJECTS MYLAN UNSOLICITED OFFER Offer Significantly Below Prior Proposal Based on Unaffected Mylan Stock Price Shareholders are Strongly Advised to Take No Action in Relation to the Offer Dublin, Ireland – April 24, 2015– Perrigo Company plc (PRGO) today announced its rejection of the unsolicited offer from Mylan NV (MYL) to acquire all of the outstanding shares of Perrigo (PRGO) for $60.00 per share i...

  10. Show article details.

    Perrigo Rejects Mylan Unsolicited Offer

    PR Newswire – 12:09 PM ET 04/24/2015

    DUBLIN, April 24, 2015 Perrigo Company plc (PRGO) today announced its rejection of the unsolicited offer from Mylan NV (MYL) to acquire all of the outstanding shares of Perrigo (PRGO) for $60.00 per share in cash and 2.2 Mylan ordinary shares for each ordinary Perrigo (PRGO) share.

  11. Show article details.

    Mylan Raises Bid for Generic Drug Maker Perrigo -- 4th Update

    DJ Business News – 12:01 PM ET 04/24/2015

    Mylan NV (MYL) raised its offer to buy generic drug maker Perrigo Co. (PRGO) to about $33 billion, the latest move in a three- way takeover tussle in the pharmaceutical industry. Mylan, which saw an earlier offer spurned by Perrigo (PRGO) this week, said its latest bid consists of $60 in cash and 2.2 Mylan shares for each share of Perrigo (PRGO). Based on Thursday's close, the offer values Perrigo (PRGO) at about $222 a share.

  12. Show article details.

    Mylan tries to fend off Teva with bigger bid for Perrigo

    MarketWatch – 11:49 AM ET 04/24/2015

    Ups the ante with $33 billion takeover proposal. The three-ring merger circus under way in generic drug making started to look more like a high-wire act Friday as Mylan NV (MYL) upped the ante for Perrigo Co. (PRGO) to fend off a takeover bid from Teva Pharmaceutical Industries Ltd. (TEVA). Dutch-based Mylan raised its bid to roughly $33 billion for Perrigo (PRGO), based in Ireland.

  13. Show article details.

    Mylan to Make Formal Bid for Perrigo -- 3rd Update

    DJ Business News – 11:06 AM ET 04/24/2015

    Mylan NV (MYL) said it will make a formal offer, worth about $33 billion in cash and stock, to buy generic drug maker Perrigo Co. (PRGO), the latest move in a three-way takeover tussle in the pharmaceutical industry. Mylan, which had indicated earlier this month that it was considering such a bid, said its offer consists of $60 in cash and 2.2 Mylan shares for each share of Perrigo (PRGO). Based on Thursday's close, the offer values Perrigo (PRGO) at about $222 a share.

  14. Show article details.

    Mylan to Make Formal Bid for Perrigo -- 2nd Update

    DJ Business News – 10:55 AM ET 04/24/2015

    Mylan NV (MYL) said it will make a formal offer, worth about $33 billion in cash and stock, to buy generic drug maker Perrigo Co. (PRGO), the latest move in a three-way takeover tussle in the pharmaceutical industry. Mylan, which had indicated earlier this month that it was considering such a bid, said its offer consists of $60 in cash and 2.2 Mylan shares for each share of Perrigo (PRGO). Based on Thursday's close, the offer values Perrigo (PRGO) at about $222 a share.

  15. Show article details.

    Mylan to Make Formal Bid for Perrigo -- Update

    DJ Business News – 10:36 AM ET 04/24/2015

    Mylan NV (MYL) said it will make a formal offer, worth about $33 billion in cash and stock, to buy generic drug maker Perrigo Co. (PRGO), the latest move in a three-way takeover tussle. Mylan, which had indicated earlier this month that it was considering such a bid, said its offer consists of $60 in cash and 2.2 Mylan shares for each share of Perrigo (PRGO). Based on Thursday's close, the offer values Perrigo (PRGO) at about $222 a share.

  16. Show article details.

    Mylan Raises Bid for Generic Drug Maker Perrigo

    DJ Business News – 10:35 AM ET 04/24/2015

    Mylan NV (MYL) raised its offer to buy generic drug maker Perrigo Co. (PRGO) to about $33 billion and was promptly rebuffed, the latest moves in a three-way takeover tussle in the pharmaceutical industry. Mylan's bid consists of $60 in cash and 2.2 Mylan shares for each share of Perrigo (PRGO). Based on Thursday's close, the offer values Perrigo (PRGO) at about $222 a share.

  17. Show article details.

    Mylan ups the ante for Perrigo with $33 billion bid

    MarketWatch – 10:23 AM ET 04/24/2015

    Mylan N.V. (MYL) upped the ante Friday in its quest for Perrigo Co. (PRGO) with a $33 billion bid for the generic drug maker. The deal is worth or $60 in cash plus 2.2 Mylan shares for each Perrigo (PRGO) share. Mylan's earlier bid for the company was rejected just as Teva Pharmaceutical Industries (TEVA) made an offer for Mylan earlier this week.

  18. Show article details.

    Mylan to Make Formal Bid for Perrigo

    DJ Business News – 10:21 AM ET 04/24/2015

    Mylan NV (MYL) said it will launch a formal offer worth about $33 billion in cash and stock to buy generic drug maker Perrigo Co. (PRGO). Mylan, which had indicated earlier this month that it was considering such a bid, said its offer consists of $60 in cash and 2.2 Mylan shares for each share of Perrigo (PRGO). Based on Thursday's close, the offer values Perrigo (PRGO) at about $222 a share.

  19. Show article details.

    Mylan says to commence offer for Perrigo

    Reuters – 10:20 AM ET 04/24/2015

    Generic drugmaker Mylan NV (MYL) said on Friday it would commence a formal offer to acquire Perrigo Co Plc (PRGO), three days after Perrigo (PRGO) rejected its unsolicited offer. Perrigo (PRGO) shareholders will receive $60 in cash and 2.2 Mylan ordinary shares for each Perrigo (PRGO) ordinary share, Mylan said.

  20. Show article details.

    Mylan To Commence Formal Offer To Acquire Perrigo For US$60 In Cash And 2.2 Mylan Shares Per Perrigo Share

    PR Newswire – 9:44 AM ET 04/24/2015

    POTTERS BAR, England, April 24, 2015 On 8 April 2015, Mylan N.V. (MYL) issued a Rule 2.4 announcement under the Irish Takeover Rules stating that it had made a non-binding proposal to acquire Perrigo for US$205 in a combination of cash and Mylan stock for each Perrigo share.

Page:

Today's and Upcoming Events

  • Apr
    30

    MYL to announce Q1 earnings Before Market (Unconfirmed)

Past Events (last 90 days)

No events in the past 90 days

Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.